|
1
|
Liu FS: Molecular carcinogenesis of
endometrial cancer. Taiwan J Obstet Gynecol. 46:26–32. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sasnauskienė A, Jonušienė V,
Krikštaponienė A, Butkytė S, Dabkevičienė D, Kanopienė D,
Kazbarienė B and Didžiapetrienė J: NOTCH1, NOTCH3, NOTCH4, and JAG2
protein levels in human endometrial cancer. Medicina (Kaunas).
50:14–18. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Elbasateeny SS, Salem AA, Abdelsalam WA
and Salem R: Immunohistochemical expression of cancer stem cell
related markers CD44 and CD133 in endometrial cancer. Pathol Res
Pract. 212:10–16. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Y, Zhang X, Ge J, Liu X, Xu S, Zhu Z,
Fang G, Liu J, Zhang H and Sun X: Can Nup88 expression be
associated with atypical endometrial hyperplasia and endometrial
cancer? A preliminary study. Pathol Res Pract. 212:274–278. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Agopianz M, Forgez P, Casse JM, Lacomme S,
Charra-Brunaud C, Clerc-Urmès I, Morel O, Bonnet C, Guéant JL,
Vignaud JM, et al: Expression of neurotensin receptor 1 in
endometrial adenocarcinoma is correlated with histological grade
and clinical outcome. Virchows Arch. 471:521–530. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Khabaz MN, Abdelrahman AS, Butt NS,
Al-Maghrabi B and Al-Maghrabi J: Cyclin D1 is significantly
associated with stage of tumor and predicts poor survival in
endometrial carcinoma patients. Ann Diagn Pathol. 30:47–51. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mittal P, Klingler-Hoffmann M, Arentz G,
Winderbaum L, Kaur G, Anderson L, Scurry J, Leung Y, Stewart CJ,
Carter J, et al: Annexin A2 and alpha actinin 4 expression
correlates with metastatic potential of primary endometrial cancer.
Biochim Biophys Acta Proteins Proteom. 1865:846–857. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Qiu M, Bao W, Wang J, Yang T, He X, Liao Y
and Wan X: FOXA1 promotes tumor cell proliferation through AR
involving the Notch pathway in endometrial cancer. BMC Cancer.
14:782014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gu X, Liu Q, Yang N, Shen JF, Zhang XG,
Cao F and Ding HZ: Clinicopathological significance of increased
ZIC1 expression in human endometrial cancer. J Huazhong Univ Sci
Technolog Med Sci. 35:898–903. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bansal N, Yendluri V and Wenham RM: The
molecular biology of endometrial cancers and the implications for
pathogenesis, classification, and targeted therapies. Cancer
Control. 16:8–13. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dohi S, Ohno S, Ohno Y, Kyo S, Soma G,
Sugiyama H and Inoue M: WT1 expression correlates with angiogenesis
in endometrial cancer tissue. Anticancer Res. 30:3187–3192.
2010.PubMed/NCBI
|
|
12
|
Stambolic V, Suzuki A, de la Pompa JL,
Brothers GM, Mirtsos C, Sasaki T, Ruland J, Penninger JM,
Siderovski DP and Mak TW: Negative regulation of PKB/Akt-dependent
cell survival by the tumor suppressor PTEN. Cell. 95:29–39. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Scully MM, Palacios-Helgeson LK, Wah LS
and Jackson TA: Rapid estrogen signaling negatively regulates PTEN
activity through phosphorylation in endometrial cancer cells. Horm
Cancer. 5:218–231. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Erkanli S, Kayaselcuk F, Kuscu E, Bagis T,
Bolat F, Haberal A and Demirhan B: Expression of survivin, PTEN and
p27 in normal, hyperplastic, and carcinomatous endometrium. Int J
Gynecol Cancer. 16:1412–1418. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Konopka B, Paszko Z, Janiec-Jankowska A
and Goluda M: Assessment of the quality and frequency of mutations
occurrence in PTEN gene in endometrial carcinomas and hyperplasias.
Cancer Lett. 178:43–51. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kimura F, Watanabe J, Hata H, Fujisawa T,
Kamata Y, Nishimura Y, Jobo T and Kuramoto H: PTEN
immunohistochemical expression is suppressed in G1 endometrioid
adenocarcinoma of the uterine corpus. J Cancer Res Clin Oncol.
130:161–168. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Machwinnie N and Monaghan H: The use of
P53, PTEN, and C-erbB-2 to differentiate uterine serous papillary
carcinoma from endometrioid endometrial carcinoma. Int J Gynecol
Cancer. 14:938–946. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kapucuoglu N, Aktepe F, Kaya H, Bircan S,
Karahan N and Ciriş M: Immunohistochemical expression of PTEN in
normal, hyperplastic and malignant endometrium and its correlation
with hormone receptors, bcl-2, bax, and apoptotic index. Pathol Res
Pract. 203:153–162. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kanamori Y, Kigawa J, Itamochi H, Sultana
H, Suzuki M, Ohwada M, Kamura T, Sugiyama T, Kikuchi Y, Kita T, et
al: PTEN expression is associated with prognosis for patients with
advanced endometrial carcinoma undergoing postoperative
chemotherapy. Int J Cancer. 100:686–689. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Mayo LD, Dixon JE, Durden DL, Tonks NK and
Donner DB: PTEN protects p53 from Mdm2 and sensitizes cancer cells
to chemotherapy. J Biol Chem. 277:5484–5489. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Garg K, Broaddus RR, Soslow RA, Urbauer
DL, Levine DA and Djordjevic B: Pathologic scoring of PTEN
immunohistochemistry in endometrial carcinoma is highly
reproducible. Int J Gynecol Pathol. 31:48–56. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jeczen R, Skomra D, Cybulski M,
Scheider-Stock R, Szewczuk W, Roessner A, Rechberger T and Semczuk
A: P53/MDM2 overexpression in metastatic endometrial cancer:
correlation with clinicopathological features and patient outcome.
Clin Exp Metastasis. 24:503–511. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pallares J, Bussaglia E, Martínez-Guitarte
JL, Dolcet X, Llobet D, Rue M, Sanchez-Verde L, Palacios J, Prat J
and Matias-Guiu X: Immunohistochemical analysis of PTEN in
endometrial carcinoma: A tissue microarray study with a comparison
of four commercial antibodies in correlation with molecular
abnormalities. Mod Pathol. 18:719–727. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Westin SN, Ju Z, Broaddus RR, Krakstad C,
Li J, Pal N, Lu KH, Coleman RL, Hennessy BT, Klempner SJ, et al:
PTEN loss is a context-dependent outcome determinant in obese and
non-obese endometrioid endometrial cancer patients. Mol Oncol.
9:1694–1703. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen J, Li S, Yang Z, Lu G and Hu H:
Correlation between NDRG1 and PTEN expression in endometrial
carcinoma. Cancer Sci. 99:706–710. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lacey JV Jr, Mutter GL, Ronnett BM, Ioffe
OB, Duggan MA, Rush BB, Glass AG, Richesson DA, Chatterjee N,
Langholz B and Sherman ME: PTEN expression in endometrial biopsies
as a marker of progression to endometrial carcinoma. Cancer Res.
68:6014–6020. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Merritt MA and Cramer DW: Molecular
pathogenesis of endometrial and ovarian cancer. Cancer Biomark.
9:287–305. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Fadare O and Parksh V: p53 aberrations in
low grade endometrioid carcinoma of the endometrium with nodal
metastases: Possible insights on pathogenesis discerned from
immunohistochemistry. Diagn Pathol. 12:812017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jiang Z, Xu W, Dan G, Liu Y and Xiong J:
P53 and murine double minute 2 (MDM2) expression changes and
significance in different types of endometrial lesions. Med Sci
Monit. 22:4786–4793. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kounelis S, Kapranos N, Kouri E, Coppola
D, Papadaki H and Jones MW: Immunohistochemical profile of
endometrial adenocarcinoma: A study of 61 cases and review of the
literature. Mod Pathol. 13:379–388. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Mazurek A, Kuć P, Mazurek-Wadołkowska E
and Laudański T: A role of thymidine phosphorylase and P53 tissue
protein expression in biology of endometrial cancer. Neoplasma.
55:261–265. 2008.PubMed/NCBI
|
|
32
|
Oda K, Okada J, Timmerman L,
Rodriguez-Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H,
Knight ZA, Shokat KM and McCormick F: PIK3CA cooperates with other
phosphatidylinositol 3′-kinase pathway mutations to effect
oncogenic transformation. Cancer Res. 68:8127–8136. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li SF, Shiozawa T, Nakayama K, Nikaido T
and Fujii S: Stepwise abnormality of sex steroid hormone receptors,
tumor suppressor gene products (p53 and Rb), and cyclin E in
uterine endometrioid carcinoma. Cancer. 77:321–329. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ozkara SK and Corakci A: Significantly
decreased P27 expression in endometrial carcinoma compared to
complex hyperplasia with atypia (correlation with p53 expression).
Pathol Oncol Res. 10:89–97. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Edmondson RJ, Crosbie EJ, Nickkho-Amiry M,
Kaufmann A, Stelloo E, Nijman HW, Leary A, Auguste A, Mileshkin L,
Pollock P, et al: Markers of the p53 pathway further refine
molecular profiling in high-risk endometrial cancer: A TransPORTEC
initiative. Gynecol Oncol. 146:327–333. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Suzuki C, Matsumoto T, Sonoue H, Arakawa
A, Furugen Y and Kinoshita K: Prognostic significance of the
infiltrative pattern invasion in endometrioid adenocarcinoma of the
endometrium. Pathol Int. 53:495–500. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Ambros RA, Ross JS, Kallakury BV,
Malfetano J, Kim Y, Hwang J, Breese K and Figge J: p53 gene status
in endometrial carcinomas showing diffuse positivity for p53
protein by immunohistochemical analysis. Mod Pathol. 8:441–445.
1995.PubMed/NCBI
|
|
38
|
Ambros RA, Sheehan CE, Kallakury BV, Ross
JS, Malfetano J, Paunovich E and Figge J: MDM2 and p53 protein
expression in the histologic subtypes of endometrial carcinoma. Mod
Pathol. 9:1165–1169. 1996.PubMed/NCBI
|
|
39
|
Tashiro H, Blazes MS, Wu R, Cho KR, Bose
S, Wang SI, Li J, Parsons R and Ellenson LH: Mutations in PTEN are
frequent in endometrial carcinoma but rare in other common
gynecological malignancies. Cancer Res. 57:3935–3940.
1997.PubMed/NCBI
|
|
40
|
Sakuragi N, Hirai A, Tada M, Yamada H,
Yamamoto R, Fujimoto S and Moriuchi T: Dominant-negative mutation
of p53 tumor suppressor gene in endometrial carcinoma. Gynecol
Oncol. 83:485–490. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Appel ML, Edelweiss MI, Fleck J, Rivero
LF, Rivoire WA, Mônego HI and Dos Reis R: P53 and BCL-2 as
prognostic markers in endometrial carcinoma. Pathol Oncol Res.
14:23–30. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Athanassiadou P, Athanassiades P, Grapsa
D, Gonidi M, Athanassiadou AM, Stamati PN and Patsouris E: The
prognostic value of PTEN, p53, and beta-catenin in endometrial
carcinoma: A prospective immunocytochemical study. Int J Gynecol
Cancer. 17:697–704. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Ellenson LH: Early molecular changes in
endometrial cancer. Int J Gynecol Cancer. 15:399–400. 2005.
View Article : Google Scholar
|
|
44
|
Lax SF: Molecular genetic pathways in
various types of endometrial carcinoma: From a phenotypical to a
molecular-based classification. Virchows Arch. 444:213–223. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Darvishian F, Hummer AJ, Thaler HT,
Bhargava R, Linkov I, Asher M and Soslow RA: Serous endometrial
cancers that mimic endometrioid adenocarcinomas: A
clinicopathologic and immunohistochemical study of a group of
problematic cases. Am J Surg Pathol. 28:1568–1578. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Cancer Genome Atlas Research Network, ;
Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H,
Robertson AG, Pashtan I, Shen R, et al: Integrated genomic
characterization of endometrial carcinoma. Nature. 497:67–73. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Fadare O and Zheng W: Insights into
endometrial serous carcinogenesis and progression. Int J Clin Exp
Pathol. 2:411–432. 2009.PubMed/NCBI
|
|
48
|
Fadare O, Gwin K, Desouki MM, Crispens MA,
Jones HW III, Khabele D, Liang SX, Zheng W, Mohammed K, Hecht JL
and Parkash V: The clinicopathologic significance of p53 and
BAF-250a (ARID1A) expression in clear cell carcinoma of the
endometrium. Mod Pathol. 26:1101–1110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Ramalingam P, Masand RP, Eucher ED and
Malpica A: Undifferentiated carcinoma of the endometrium: An
expanded immunohistochemical analysis including PAX-8 and
basal-like carcinoma surrogate markers. Int J Gynecol Pathol.
35:410–418. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Hoang LN, Lee YS, Karnezis AN,
Tessier-Cloutier B, Almandani N, Coatham M, Gilks CB, Soslow RA,
Stewart CJ, Köbel M and Lee CH: Immunophenotypic features of
dedifferentiated endometrial carcinoma-insights from
BRG1/INI1-deficient tumours. Histopathology. 69:560–569. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lopez-Garcia MA and Palacios J: Pathologic
and molecular features of uterine carcinosarcomas. Semin Diagn
Pathol. 27:274–286. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cherniack AD, Shen H, Walter V, Stewart C,
Murray BA, Bowlby R, Hu X, Ling S, Soslow RA, Broaddus RR, et al:
Integrated molecular characterization of uterine carcinosarcoma.
Cancer Cell. 31:411–423. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Alvarez T, Miller E, Duska L and Oliva E:
Molecular profile of grade 3 endometrioid endometrial carcinoma: Is
it a type I or type II endometrial carcinoma? Am J Surg Pathol.
36:753–761. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Sherman ME, Bur ME and Kurman RJ: p53 in
endometrial cancer and its putative precursors: Evidence for
diverse pathways of tumorigenesis. Hum Pathol. 26:1268–1274. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Moll MU, Chalas E, Auguste M, Meaney D and
Chumas J: Uterine papillary serous carcinoma evolves via a
p53-driven pathway. Hum Pathol. 27:1295–1300. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Zheng W, Cao P, Zheng M, Kramer EE and
Godwin TA: p53 overexpression and bcl-2 persistence in endometrial
carcinoma: Comparison of papillary serous and endometrioid
subtypes. Gynecol Oncol. 61:167–174. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Bur ME, Perlman C, Edelmann BS, Fey E and
Rose PG: p53 expression in neoplasms of the uterine corpus. Am J
Clin Pathol. 98:81–87. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Inoue M, Fujita M, Enomoto T, Morimoto H,
Monden T, Shinano T and Tanizawa O: Immunohistochemical analysis of
p53 in gynecologic tumors. Am J Clin Pathol. 102:665–670. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Prat J, Oliva E, Lerma E, Vaquero M and
Matías-Guiu X: Uterine papillary serous adenocarcinoma. A 10-case
study of p53 and c-erbB-2 expression and DNA content. Cancer.
74:1778–1783. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Reinartz JS, George E, Lindgren BR and
Niehans GA: Expression of p53, transforming growth factor alpha,
epidermal growth factor receptor, and c-erbB-2 in endometrial
carcinoma and correlation with survival and known predictors of
survival. Hum Pathol. 25:1075–1083. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Khalifa MA, Mannel RS, Haraway SD, Walker
J and Min KW: Expression of EGFR, HER-2/neu, P53, and PCNA in
endometrioid, serous papillary, and clear cell endometrial
adenocarcinomas. Gynecol Oncol. 53:84–92. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
King SA, Adas AA, LiVolsi VA, Takahashi H,
Behbakht K, McGovern P, Benjamin I, Rubin SC and Boyd J: Expression
and mutation analysis of the p53 gene in uterine papillary serous
carcinoma. Cancer. 75:2700–2705. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Tashiro H, Isacson C, Levine R, Kurman RJ,
Cho KR and Hedrick L: p53 gene mutations are common in uterine
serous carcinoma and occur early in their pathogenesis. Am J
Pathol. 150:177–185. 1997.PubMed/NCBI
|
|
64
|
Soslow RA, Shen PU, Chung MH and Isacson
C: Distinctive p53 and mdm2 immunohistochemical expression profiles
suggest different pathogenetic pathways in poorly differentiated
endometrial carcinoma. Int J Gynecol Pathol. 17:129–134. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Garcia-Dios DA, Lambrechts D, Coenegrachts
L, Vandenput I, Capoen A, Webb PM, Ferguson K; ANECS, Akslen LA,
Claes B, et al: High-throughput interrogation of PIK3CA, PTEN,
KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Gynecol Oncol. 128:327–334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Seeger A, Kölbl H, Petry IB, Gebhard S,
Battista MJ, Böhm D and Steiner E: p53 is correlated with low BMI
negative progesterone receptor status and recurring disease in
patients with endometrial cancer. Gynecol Oncol. 125:200–207. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Urabe R, Hachisuga T, Kurita T, Kagami S,
Kawagoe T, Matsuura Y and Shimajiri S: Prognostic significance of
overexpression of p53 in uterine endometrioid adenocarcinomas with
an analysis of nuclear grade. J Obstet Gynaecol Res. 40:812–819.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Lee EJ, Kim TJ, Kim DS, Choi CH, Lee JW,
Lee JH, Bae DS and Kim BG: p53 alteration independently predicts
poor outcomes in patients with endometrial cancer: A
clinicopathologic study of 131 cases and literature review. Gynecol
Oncol. 116:533–538. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kurnit KC, Kim GN, Fellman BM, Urbauer DL,
Mills GB, Zhang W and Broaddus RR: CTNNB1 (beta-catenin) mutation
identifies low grade, early stage endometrial cancer patients at
increased risk of recurrence. Mod Pathol. 30:1032–1041. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Daniilidou K, Frangou-Plemenou M,
Grammatikakis J, Grigoriou O, Vitoratos N and Kondi-Pafiti A:
Prognostic significance and diagnostic value of PTEN and p53
expression in endometrial carcinoma. A retrospective
clinicopathological and immunohistochemical study. J BUON.
18:195–201. 2013.PubMed/NCBI
|
|
71
|
Ohkouchi T, Sakuragi N, Watari H, Nomura
E, Todo Y, Yamada H and Fujimoto S: Prognostic significance of
Bcl-2, p53 overexpression, and lymph node metastasis in surgically
staged endometrial carcinoma. Am J Obstet Gynecol. 187:353–359.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Erdem O, Erdem M, Dursun A, Akyol G and
Erdem A: Angiogenesis, p53, and bcl-2 expression as prognostic
indicators in endometrial cancer: comparison with traditional
clinicopathologic variables. Int J Gynecol Pathol. 22:254–260.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Hirschowitz L, Ganesan R and McCluggage
WG: WT1, p53 and hormone receptor expression in uterine serous
carcinoma. Histopathology. 55:478–482. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Mariani A, Sebo TJ, Webb MJ, Riehle D,
Katzmann JA, Keeney GL, Roche PC, Lesnick TG and Podratz KC:
Molecular and histopathologic predictors of distant failure in
endometrial cancer. Cancer Detect Prev. 27:434–441. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Ito K, Watanabe K, Nasim S, Sasano H, Sato
S, Yajima A, Silverberg SG and Garrett CT: Prognostic significance
of p53 overexpression in endometrial cancer. Cancer Res.
54:4667–4670. 1994.PubMed/NCBI
|
|
76
|
Alkushi A, Lim P, Coldman A, Huntsman D,
Miller D and Gilks CB: Interpretation of p53 immunoreactivity in
endometrial carcinoma: Establishing a clinically relevant cut-off
level. Int J Gynecol Pathol. 23:129–137. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Hamel NW, Sebo TJ, Wilson TO, Keeney GL,
Roche PC, Suman VJ, Hu TC and Podratz KC: Prognostic value of p53
and proliferating cell nuclear antigen expression in endometrial
carcinoma. Gynecol Oncol. 62:192–198. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Bancher-Todesca D, Gitsch G, Williams KE,
Kohlberger P, Neunteufel W, Obermair A, Heinze G, Breitenecker G
and Hacker NF: p53 protein overexpression: A strong prognostic
factor in uterine papillary serous carcinoma. Gynecol Oncol.
71:59–63. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Geisler JP, Geisler HE, Wiemann MC, Zhou
Z, Miller GA and Crabtree W: p53 expression as a prognostic
indicator of 5-year survival in endometrial cancer. Gynecol Oncol.
74:468–471. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Oreskovic S, Babic D, Kalafatic D, Barisic
D and Beketic-Oreskovic L: A significance of immunohistochemical
determination of steroid receptors, cell proliferation factor Ki-67
and protein p53 in endometrial carcinoma. Gynecol Oncol. 93:34–40.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Osmanağaoğlu MA, Kadioğlu S, Osmanağaoğlu
S, Bozkaya H, Reis A and Tekelioğlu Y: The relationship between
mutant p53 gene, DNA contents and conventional clinicopathological
prognostic variables in cases with endometrial carcinoma. Eur J
Gynaecol Oncol. 26:64–70. 2005.PubMed/NCBI
|
|
82
|
Soong R, Knowles S, Williams KE, Hammond
IG, Wysocki SJ and Iacopetta BJ: Overexpression of p53 protein is
an independent prognostic indicator in human endometrial carcinoma.
Br J Cancer. 74:562–567. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Jeon YT, Kang S, Kang DH, Yoo KY, Park IA,
Bang YJ, Kim JW, Park NH, Kang SB, Lee HP and Song YS:
Cyclooxygenase-2 and p53 expression in endometrial cancer. Cancer
Epidemiol Biomarkers Prev. 13:1538–1542. 2004.PubMed/NCBI
|
|
84
|
Risinger JI, Hayes K, Maxwell GL, Carney
ME, Dodge RK, Barrett JC and Berchuck A: PTEN Mutation in
endometrial cancers is associated with favorable clinical and
pathologic characteristics. Clin Cancer Res. 4:3005–3010.
1998.PubMed/NCBI
|
|
85
|
Maxwell GL, Risinger JI, Hayes KA, Alvarez
AA, Dodge RK, Barrett JC and Berchuck A: Racial disparity in the
frequency of PTEN mutations, but not microsatellite instability, in
advanced endometrial cancers. Clin Cancer Res. 6:2999–3005.
2000.PubMed/NCBI
|
|
86
|
Levine RL, Cargile CB, Blazes MS, van Rees
B, Kurman RJ and Ellenson LH: PTEN mutations and microsatellite
instability in complex atypical hyperplasia, a precursor lesion to
uterine endometrioid carcinoma. Cancer Res. 58:3254–3258.
1998.PubMed/NCBI
|
|
87
|
Yoshinaga K, Sasano H, Furukawa T,
Yamakawa H, Yuki M, Sato S, Yajima A and Horii A: The PTEN, BAX,
and IGFIIR genes are mutated in endometrial atypical hyperplasia.
Jpn J Cancer Res. 89:985–990. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Mutter GL, Lin MC, Fitzgerald JT, Kum JB,
Baak JP, Lees JA, Weng LP and Eng C: Altered PTEN expression as a
diagnostic marker for the earliest endometrial precancers. J Natl
Cancer Inst. 92:924–930. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Peiffer SL, Herzog TJ, Tribune DJ, Mutch
DG, Gersell DJ and Goodfellow PJ: Allelic loss of sequences from
the long arm of chromosome 10 and replication errors in endometrial
cancers. Cancer Res. 55:1922–1926. 1995.PubMed/NCBI
|
|
90
|
Nagase S, Sato S, Tezuka F, Wada Y, Yajima
A and Horii A: Deletion mapping on chromosome 10q25-q26 in human
endometrial cancer. Br J Cancer. 74:1979–1983. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Akiyama-Abe A, Minaguchi T, Nakamura Y,
Michikami H, Shikama A, Nakao S, Sakurai M, Ochi H, Onuki M,
Matsumoto K, et al: Loss of PTEN expression is an independent
predictor of favourable survival in endometrial carcinomas. Br J
Cancer. 109:1703–1710. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Bussaglia E, del Rio E, Matias-Guiu X and
Prat J: PTEN mutations in endometrial carcinomas: A molecular and
clinicopathologic analysis of 38 cases. Hum Pathol. 31:312–317.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Kanamori Y, Kigawa J, Itamochi H, Shimada
M, Takahashi M, Kamazawa S, Sato S, Akeshima R and Terakawa N:
Correlation between loss of PTEN expression and Akt phosphorylation
in endometrial carcinoma. Clin Cancer Res. 7:892–895.
2001.PubMed/NCBI
|
|
94
|
Minaguchi T, Yoshikawa H, Oda K, Ishino T,
Yasugi T, Onda T, Nakagawa S, Matsumoto K, Kawana K and Taketani Y:
PTEN mutation located only outside exons 5, 6, and 7 is an
independent predictor of favorable survival in endometrial
carcinomas. Clin Cancer Res. 7:2636–2642. 2001.PubMed/NCBI
|
|
95
|
Dellas A, Jundt G, Sartorius G, Schneider
M and Moch H: Combined PTEN and p27kip1 protein expression patterns
are associated with obesity and prognosis in endometrial
carcinomas. Clin Cancer Res. 15:2456–2462. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Mackay HJ, Gallinger S, Tsao MS, McLachlin
CM, Tu D, Keiser K, Eisenhauer EA and Oza AM: Prognostic value of
microsatellite instability (MSI) and PTEN expression in women with
endometrial cancer: Results from studies of the NCIC Clinical
Trials Group (NCIC CTG). Eur J Cancer. 46:1365–1373. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Terakawa N, Kanomori Y and Yoshida S: Loss
of PTEN expression followed by Akt phosphorylation is poor
prognostic factor for patients with endometrial cancer. Endocr
Relat Cancer. 10:203–208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Salvesen HB, Stefansson I, Kalvenes MB,
Das S and Akslen LA: Loss of PTEN expression is associated with
metastatic disease in patients with endometrial carcinoma. Cancer.
94:2185–2191. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Catasus L, Gallardo A, Cuatrecasas M and
Prat J: Concomitant PI3K-AKT and p53 alterations in endometrial
carcinomas are associated with poor prognosis. Mod Pathol.
22:522–529. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Nout RA, Bosse T, Creutzberg CL,
Jürgenliemk-Schulz IM, Jobsen JJ, Lutgens LC, van der Steen-Banasik
EM, van Eijk R, Ter Haar NT and Smit VT: Improved risk assessment
of endometrial cancer by combined analysis of MSI, PI3K-AKT,
Wnt/β-catenin and P53 pathway activation. Gynecol Oncol.
126:466–473. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Uegaki K, Kanamori Y, Kigawa J, Kawaguchi
W, Kaneko R, Naniwa J, Takahashi M, Shimada M, Oishi T, Itamochi H
and Terakawa N: PTEN-positive and phosphorylated-Akt-negative
expression is a predictor of survival for patients with advanced
endometrial carcinoma. Oncol Rep. 14:389–392. 2005.PubMed/NCBI
|
